Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

319 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Barriers to implementing screening, brief intervention and referral to treatment for substance use in HIV/AIDS health services in Peru].
Hoffman KA, Beltrán J, Ponce J, García-Fernandez L, Calderón M, Muench J, Benites C, Soto L, McCarty D, Fiestas F. Hoffman KA, et al. Among authors: soto l. Rev Peru Med Exp Salud Publica. 2016 Jul-Sep;33(3):432-437. doi: 10.17843/rpmesp.2016.333.2293. Rev Peru Med Exp Salud Publica. 2016. PMID: 27831605 Free article. Spanish.
Recovery of HIV antigen in peritoneal dialysis fluid.
Correa-Rotter R, Saldivar S, Soto LE, Ponce de Leon S, Ojeda F, Ruiz-Palacios G, Pena JC. Correa-Rotter R, et al. Among authors: soto le. Perit Dial Int. 1990;10(1):67-9. Perit Dial Int. 1990. PMID: 2085586
Early hepatitis C virus changes and sustained response in patients with chronic hepatitis C treated with peginterferon alpha-2b and ribavirin.
Gallegos-Orozco JF, Loaeza-del Castillo A, Fuentes AP, García-Sandoval M, Soto L, Rodríguez R, Gutiérrez-Ruíz MC, Gutiérrez-Reyes G, Bonder A, Olivera MA, Kershenobich D. Gallegos-Orozco JF, et al. Among authors: soto l. Liver Int. 2005 Feb;25(1):91-5. doi: 10.1111/j.1478-3231.2005.1040.x. Liver Int. 2005. PMID: 15698404 Clinical Trial.
Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial.
Kenemans P, Bundred NJ, Foidart JM, Kubista E, von Schoultz B, Sismondi P, Vassilopoulou-Sellin R, Yip CH, Egberts J, Mol-Arts M, Mulder R, van Os S, Beckmann MW; LIBERATE Study Group. Kenemans P, et al. Lancet Oncol. 2009 Feb;10(2):135-46. doi: 10.1016/S1470-2045(08)70341-3. Epub 2009 Jan 23. Lancet Oncol. 2009. PMID: 19167925 Free article. Clinical Trial.
Oral estrogen receptor PROTAC® vepdegestrant (ARV-471) is highly efficacious as monotherapy and in combination with CDK4/6 or PI3K/mTOR pathway inhibitors in preclinical ER+ breast cancer models.
Gough SM, Flanagan JJ, Teh J, Andreoli M, Rousseau E, Pannone M, Bookbinder M, Willard R, Davenport K, Bortolon E, Cadelina G, Gordon D, Pizzano J, Macaluso J, Soto L, Corradi J, Digianantonio K, Drulyte I, Morgan A, Quinn C, Békés M, Ferraro C, Chen X, Wang G, Dong H, Wang J, Langley DR, Houston J, Gedrich R, Taylor IC. Gough SM, et al. Among authors: soto l. Clin Cancer Res. 2024 May 31. doi: 10.1158/1078-0432.CCR-23-3465. Online ahead of print. Clin Cancer Res. 2024. PMID: 38819400
319 results